Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Straight Talk About Cancer Drug Coverage

This article was originally published in RPM Report

Executive Summary

CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.

You may also be interested in...



It’s Official: FDA Approval Does Not Equal CMS Coverage

Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.

What Will CMS Do With Avastin In Breast Cancer?

With FDA’s decision to pull the indication for Avastin in breast cancer, CMS is now waiting and watching for residual use patterns.

What New Cancer Pathway Programs Mean For The Drug Industry

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel